Kineta to Receive $5 Million Milestone Payment from Merck
Discovery stage milestone triggered by validating an undisclosed target for amyotrophic lateral sclerosis (ALS) SEATTLE, June 29, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune [...]